Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
Other Sizes |
|
Purity: ≥98%
Cinepazide maleate (NSC291562; MD-67350; MD67350; Brendil; Vasodistal; Kelinao or Anjieli), the maleate salt form of cinepazide,is a vasodilator used in China for the treatment of cardiovascular, cerebrovascular, and peripheral vascular diseases. It was reported to work by potentiating A2 adenosine receptors.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
Cinnarizine lessens the effects of intravertebral adenosine and cyclic AMP on dogs' vertebral vasodilator response, but cinepazide Maleate (intravenous injection; 30 mg/kg) increases it[1]. In dogs, dose-related increases in vertebral blood flow are observed with Cinepazide Maleate (intravertebral injection; 1–10 mg/kg)[1].
|
||
Animal Protocol |
|
||
References |
[1]. Akashi, A., et al., [Cardiovascular pharmacology of cinepazide, a new cerebral vasodilator (author's transl)]. Nihon Yakurigaku Zasshi, 1979. 75(5): p. 507-16.
[2]. Jun Ni , et al. Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial. BMC Neurol. 2020 Jul 14;20(1):282. |
Molecular Formula |
C22H31N3O5.C4H4O4
|
|
---|---|---|
Molecular Weight |
533.57
|
|
CAS # |
26328-04-1
|
|
Related CAS # |
23887-46-9
|
|
SMILES |
O=C(C([H])([H])N1C([H])([H])C([H])([H])N(C(/C(/[H])=C(\[H])/C2C([H])=C(C(=C(C=2[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])=O)C([H])([H])C1([H])[H])N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H].O([H])C(C([H])=C([H])C(=O)O[H])=O
|
|
InChi Key |
XSTJTOKYCAJVMJ-GVTSEVKNSA-N
|
|
InChi Code |
InChI=1S/C22H31N3O5.C4H4O4/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24;5-3(6)1-2-4(7)8/h6-7,14-15H,4-5,8-13,16H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b7-6+;2-1-
|
|
Chemical Name |
1-[(1-Pyrrolidinylcarbonyl)methyl]-4-(3,4,5-trimethoxycinnamoyl)piperazine Maleate
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8742 mL | 9.3708 mL | 18.7417 mL | |
5 mM | 0.3748 mL | 1.8742 mL | 3.7483 mL | |
10 mM | 0.1874 mL | 0.9371 mL | 1.8742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.